Advertisement
Screener

Spruce Biosciences, Inc. (SPRB) Long-Term Debt, Maturity, Remainder of Fiscal Year

Spruce Biosciences, Inc. Long-Term Debt, Maturity, Remainder of Fiscal Year

Spruce Biosciences, Inc. (SPRB) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $450.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-12.

Financial Statements › Notes › Commitment and Contingencies

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2024-11-12

  • 2024-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $450.00K.
  • 2020-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
Period endLong-Term Debt, Maturity, Remainder of Fiscal Year
2024-09-30$450.00K
10-Q · filed 2024-11-12
2020-09-30$0.00
10-Q · filed 2020-11-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
Atrium Therapeutics, Inc. (RNA)United States$0.140B
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
Annexon, Inc. (ANNX)United States$0.147B-4.22
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
IMMUNIC, INC. (IMUX)United States$0.127B-1.88